Modified IL-4 mutein receptor antagonists

US7785580B2 · kind B2 · utility

Assignee

• Aerovance, Inc. · US

Inventors

• Clark Pan · Sudbury, US
• Steve Roczniak · Lafayette, US
• Jeffrey Greve · Branford, US
• Stephanie Yung · San Francisco, US
• Malinda Longphre · Oakland, US
• Teresa Mo-Fun Wong · Lafayette, US
• Adrian Tomkinson · Corona, US
• David Boisvert · Corona, US
• Elise Burmeister-Getz · Berkeley, US
• Kathy Delaria · Walnut Creek, US

Key dates

• Filing date: Nov 14, 2007
• Grant date: Aug 31, 2010
• Expiry date: Nov 14, 2027

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K38/00
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to modified IL-4 mutein receptor antagonists comprising an IL-4 mutein receptor antagonist coupled to polyethylene glycol. Related formulations and dosages and methods of administration thereof for therapeutic purposes are also provided. These modified IL-4 mutein receptor antagonists, compositions and methods provide a treatment option for those individuals afflicted with a respiratory disorder such as asthma by inhibiting IL-4 and IL-13-mediated airway hyperresponsiveness and eosinophilia. More particularly, these antagonists have an increased duration of effect versus unmodified IL-4RA by virtue of a greater plasma half-life.